title: Delamanid: A new armor in combating drug-resistant tuberculosis.
abstract: Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
authors.affiliation: Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
authors.forename: Alphienes Stanley
authors.initials: AS
authors.lastname: Xavier
authors.affiliation: Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
authors.forename: Mageshwaran
authors.initials: M
authors.lastname: Lakshmanan
keywords: Delamanid; multidrug-resistant tuberculosis; mycolic acid inhibitor